A randomized , double-blind trial was conducted in 42 obese , unmedicated individuals with metabolic syndrome ( mean age 56 1 y , body mass index 34 0.6 kg/m ( 2 ) ) who received 12 weeks of pioglitazone ( PIO ; 15 mg for 6 wk , then 30 mg daily ) or matched placebo .